#United States #Sacramento #Persist AI #Solubility Company #Drug Formulation

A Revolutionary Collaboration in Drug Formulation

In an impressive merger of technology and pharmaceutical innovation, The Solubility Company and Persist AI have announced a strategic partnership aimed at transforming drug formulation processes. This collaboration is particularly exciting due to its introduction of the first fully automated SPA® platform (Single Particle Analysis), which promises to change the landscape of preclinical drug development significantly.

Addressing the Solubility Conundrum

The pharmaceutical development process faces a significant challenge, with nearly 90% of potential drug candidates encountering notable solubility issues. As demand for high-quality solubility datasets grows, especially in the early discovery phases, traditional methods are often hampered by the scarcity of materials. The Solubility Company's SPA® platform adeptly counters this issue by allowing practitioners to perform high-fidelity solubility measurements with just a milligram of sample material.

The aim is to seamlessly integrate this game-changing technology into Persist AI's advanced robotic cloud laboratory framework. This integration promises to generate a feedback loop that expedites the journey of promising drug candidates towards Investigational New Drug (IND) applications.

Redefining Formulation through AI

In today's rapidly evolving landscape, artificial intelligence (AI) has demonstrated its capacity to revolutionize molecule discovery. However, the preclinical sector grapples with a stark data scarcity problem in physical chemistry. Essential datasets for preclinical applications are often either too small, inconsistent, or inadequately annotated, limiting robust machine learning application.

As Dr. Sami Svanbäck, CEO of The Solubility Company pointed out, “The industry is in a data renaissance, with data-hungry AI only as good as the physical evidence it is trained on.” The automation of the SPA® platform is expected to deliver a high-throughput engine for acquiring quality data quickly and efficiently.

Karthik Raman, CEO of Persist AI, echoed this sentiment, emphasizing a shift away from the traditional, slow cycle of trial and error. Instead, the partnership aims to incorporate a high-speed empirical augmented AI feedback loop that can drastically reduce the time spent on repetitive downstream wet-lab experimentation, allowing scientists to mitigate risks early in the formulation process.

Key Features of the Partnership

1. Automated SPA® Integration: Persist AI is developing robotics that will enable the SPA® platform to function within its automated Cloud Lab environment, allowing for ultra-low sample screening at a higher throughput than ever before.
2. Rapid Advancement to IND: Clients in the global pharmaceutical and biotech sectors will gain access to the newly automated SPA® platform via the Cloud Lab, enabling rapid progression from promising compounds to dosable formulations.
3. Collaboration on AI Models: By utilizing high-fidelity datasets, the two companies will co-develop sophisticated predictive AI models tailored for novel drug modalities in relevant preclinical scenarios.

Implications for the Future

The collaboration between The Solubility Company and Persist AI represents a pivotal transition from traditional empirical methods to a more digital-first approach in drug development. The ability to rapidly generate thousands of data points from minimal material allows researchers to identify optimal delivery vehicles significantly earlier in the development timeline.

Interested parties looking to engage in pilot programs are encouraged to reach out to the respective business development teams within each company.

About The Solubility Company

Founded with a focus on advancing drug development, The Solubility Company specializes in optimizing the transition from medicinal chemistry to clinical application. Its SPA® platform enables accurate analysis of solubility and other physicochemical properties, leveraging microscopic sample quantities.

About Persist AI

Persist AI is pioneering advancements in pharmaceutical formulation through its innovative robotic platform. Specialized in high-throughput experimentation and predictive modeling, the company enhances efficiency for partners across the biopharmaceutical landscape.

For more information on their groundbreaking initiative, visit the linked sites or contact the business development offices directly.